Nesfatin-1
Nesfatin-1 is a signalling molecule made in the brain, gut and fat tissue that reduces appetite; levels tend to be lower in people with obesity, and it is one of the body's satiety brakes.
Plain English
Patient-Friendly Explanation
Nesfatin-1 is a small protein the body makes in the brain, the stomach and fat tissue. Its best-understood job is to reduce appetite: when it is given to animals they eat less, and when its action is blocked they eat more, so it works as one of the body's natural appetite brakes. Studies in people have generally found lower levels in those carrying excess weight, and levels change after weight loss and after weight-loss surgery, although results vary between studies and measurement methods. It works alongside better known appetite hormones such as leptin, ghrelin and GLP-1. There is no nesfatin-1 medicine and no routine test for it. It is in the library because it shows appetite is a regulated system with many brakes and accelerators, not a test of willpower.
Medical
Clinical Definition
Nesfatin-1 is an 82-amino-acid anorexigenic polypeptide cleaved from the precursor nucleobindin-2 (NUCB2), expressed in the hypothalamic paraventricular and arcuate nuclei, the brainstem, pancreatic islet cells, gastric endocrine cells and adipose tissue. Central administration reduces food intake in a dose-dependent manner and delays gastric emptying; the anorexigenic effect is melanocortin-dependent (blocked by melanocortin-3/4 receptor antagonism) and leptin-independent, and it is co-expressed with oxytocin in the paraventricular nucleus. Beyond appetite, nesfatin-1 influences glucose homeostasis, insulin secretion, thermogenesis and, in some models, cardiovascular and reproductive function. In humans, circulating nesfatin-1 has been reported as lower in obesity, negatively correlated with body mass index and waist circumference in several case-control studies, and altered by diet-induced weight loss, sleeve gastrectomy and Roux-en-Y gastric bypass. The literature is nonetheless heterogeneous: some studies report unchanged or even higher levels in obesity, and results depend on assay, sample handling and whether total NUCB2 or the processed peptide is measured, because nesfatin-1 circulates partly protein-bound. It therefore remains a research biomarker: no assay is validated for clinical use and no nesfatin-1-based therapy exists. Its value in a patient-facing library is illustrative - appetite is governed by interacting orexigenic and anorexigenic signals, which is why appetite-focused treatments act on pathways rather than on willpower.
Key Insight
Why It Matters
No patient will ever have a nesfatin-1 test, but it belongs in the library because it shows appetite is a regulated system with many brakes rather than a character trait.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
